Psoriasiform Eruption Secondary to PI3K-delta Inhibitor: Expanding the Spectrum of Psoriasiform Paradoxical Reactions?

Authors

  • David Pesqué
  • Blanca Sanchez-Gonzalez
  • Fernando Gallardo Department of Dermatology, Hospital del Mar - Parc de Salut Mar, ES-08003 Barcelona, Spain
  • Sonia Segura
  • Ramon M. Pujol

DOI:

https://doi.org/10.2340/00015555-3783

Keywords:

psoriasis, paradoxical reaction, PI3K inhibitor

Abstract

Abstract is missing (Short communication)

Downloads

Download data is not yet available.

References

Goncalves MD, Hopkins BD, Cantley LC. Phosphatidylinositol 3-kinase, growth disorders, and cancer. N Engl J Med 2018; 379: 2052-2062.

DOI: https://doi.org/10.1056/NEJMra1704560

Huang T, Lin X, Meng X, Lin M. Phosphoinositide-3 kinase/protein kinase-B/mammalian target of rapamycin pathway in psoriasis pathogenesis. a potential therapeutic target? Acta DermVenerol 2014; 94: 371-379.

DOI: https://doi.org/10.2340/00015555-1737

Helmer E, Watling M, Jones E, Tytgat D, Jones M, Allen R, et al. First-in-human studies of seletalisib, an orally bioavailable small-molecule PI3K? inhibitor for the treatment of immune and inflammatory diseases. Eur J ClinPharmacol 2017; 73: 581-591.

DOI: https://doi.org/10.1007/s00228-017-2205-7

Greenwell IB, Ip A, Cohen JB. PI3K Inhibitors: understanding toxicity mechanisms and management. Oncology 2017; 31: 821-828.

Dewan AK, Gupta S, Bach DQ, Jadeja S, Granter S, LaCasce A, et al. Psoriasiform eruptions secondary to phosphoinositide 3-kinase inhibition. JAAD Case Rep 2019; 5: 401-405.

DOI: https://doi.org/10.1016/j.jdcr.2018.03.005

Machan S, Plaza C, Pérez-González Y, Rodriguez-Pinilla M, Requena L, Cordoba R. Management of psoriasis-like rash associated with idelalisib monotherapy in a patient with refractory follicular lymphoma: a case report. J Med Case Rep 2020; 14: 35.

DOI: https://doi.org/10.1186/s13256-020-2344-9

Pittini Á, Casaravilla C, Allen JE, Díaz Á. Pharmacological inhibition of PI3K class III enhances the production of pro- and anti-inflammatory cytokines in dendritic cells stimulated by TLR agonists. Int Immunopharmacol 2016; 36: 213-217.

DOI: https://doi.org/10.1016/j.intimp.2016.04.028

Kim JH, Kim WS, Park C. Interleukin-6 mediates resistance to PI3K-pathway-targeted therapy in lymphoma. BMC Cancer 2019; 19: 936.

DOI: https://doi.org/10.1186/s12885-019-6057-7

Mylonas A, Conrad C. Psoriasis: Classical vs. paradoxical. The yin-yang of TNF and type I interferon. Front Immunol 2018; 9: 2746.

DOI: https://doi.org/10.3389/fimmu.2018.02746

Downloads

Published

2021-03-18

How to Cite

Pesqué, D., Sanchez-Gonzalez, B., Gallardo, F., Segura, S., & Pujol, R. M. (2021). Psoriasiform Eruption Secondary to PI3K-delta Inhibitor: Expanding the Spectrum of Psoriasiform Paradoxical Reactions?. Acta Dermato-Venereologica, 101(3), adv00418. https://doi.org/10.2340/00015555-3783

Issue

Vol. 101 No. 3 (2021): March

Section

Short Communication

Categories

License

Copyright (c) 2021 David Pesqué, Blanca Sanchez-Gonzalez, Fernando Gallardo, Sonia Segura, Ramon M. Pujol

Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

All digitalized ActaDV contents is available freely online. The Society for Publication of Acta Dermato-Venereologica owns the copyright for all material published until volume 88 (2008) and as from volume 89 (2009) the journal has been published fully Open Access, meaning the authors retain copyright to their work.

Unless otherwise specified, all Open Access articles are published under CC-BY-NC licences, allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material for non-commercial purposes, provided proper attribution to the original work.

Crossref
Scopus
Google Scholar
Europe PMC